- Home
- CGON
CGON
CG ONCOLOGY INC
as 07-26-2024 4:00pm EST
Stocks
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Upcoming Earnings Alert:
Get ready for potential market movements as CG ONCOLOGY INC CGON prepares to release earnings report on 02 Aug 2024.
| Founded: | 2010 | Country: | Canada |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 2.1B | IPO Year: | 2024 |
| Target Price: | $64.00 | AVG Volume (30 days): | 557.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.85 | EPS Growth: | N/A |
| 52 Week Low/High: | $25.77 - $50.23 | Next Earning Date: | 08-02-2024 |
| Revenue: | $539,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 730.39% | Revenue Growth (next year): | 428.63% |
Stock Insider Trading Activity of CG ONCOLOGY INC (CGON)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Decheng Capital Global Life Sciences Fund IV, L.P. | CGON | 10% Owner | Jan 29 '24 | Buy | $19.00 | 400,000 | $7,600,000.00 | 400,000 | SEC Form 4 |
| Song Hong Fang | CGON | Director | Jan 29 '24 | Buy | $19.00 | 263,157 | $4,999,983.00 | 613,928 | SEC Form 4 |
| Decheng Capital Global Life Sciences Fund IV, L.P. | CGON | 10% Owner | Jan 29 '24 | Buy | $19.00 | 400,000 | $7,600,000.00 | 4,958,810 | SEC Form 4 |
| Roche Corleen M. | CGON | CFO & Secretary | Jan 29 '24 | Buy | $19.00 | 2,000 | $38,000.00 | 2,000 | SEC Form 4 |
| Kasturi Vijay | CGON | Chief Medical Officer | Jan 29 '24 | Buy | $19.00 | 1,315 | $24,985.00 | 1,315 | SEC Form 4 |
Latest CG ONCOLOGY INC News
CGON Breaking Stock News: Dive into CGON Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Institutional investors in CG Oncology, Inc. (NASDAQ:CGON) must be dismayed after prices dropped by 13% last week
GlobeNewswire
a month ago
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
GlobeNewswire
2 months ago
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
GlobeNewswire
2 months ago
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
GlobeNewswire
3 months ago
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
3 months ago
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
GlobeNewswire
3 months ago
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
GlobeNewswire
3 months ago
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
Compare CGON vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CGON CG ONCOLOGY INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.